Ginsenoside Rg3 inhibition of vasculogenic mimicry in pancreatic cancer through downregulation of VE-cadherin/EphA2/MMP9/MMP2 expression

International Journal of Oncology

Volumn 45, Issue 3, 2014, Pages 1065-1072

  Guo, Jing Qiang ^a   Zheng, Qing Hui ^b   Chen, Hui ^a   Chen, Liang ^a   Xu, Jin Bo ^a   Chen, Min Yuan ^a   Lu, Dian ^a   Wang, Zhao Hong ^a   Tong, Hong Fei ^a   Lin, Shengzhang ^a,c  

^a WENZHOU MEDICAL UNIVERSITY   (China)

^b GUANGXI MEDICAL UNIVERSITY   (China)

^c ZHEJIANG UNIVERSITY   (China)

Author keywords

Ginsenoside Rg3; Matrix metalloproteinase; Pancreatic cancer; Vascular endothelial cadherin; Vasculogenic mimicry

Indexed keywords

EPHRIN RECEPTOR A2; GELATINASE A; GELATINASE B; GINSENOSIDE RG 3; VASCULAR ENDOTHELIAL CADHERIN; ANTINEOPLASTIC AGENT; CADHERIN; GINSENOSIDE; LEUKOCYTE ANTIGEN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PANCREAS CANCER; PANCREATIC CANCER CELL LINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; TUMOR XENOGRAFT; WESTERN BLOTTING; XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; DRUG EFFECTS; DRUG SCREENING; EXPERIMENTAL NEOPLASM; GENE EXPRESSION REGULATION; METABOLISM; MOUSE; NEOVASCULARIZATION, PATHOLOGIC; PANCREAS DISEASE; PANCREAS TUMOR; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTIGENS, CD; ANTINEOPLASTIC AGENTS; CADHERINS; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; GINSENOSIDES; HUMANS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MICE; MICE, INBRED BALB C; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; PANCREATIC DISEASES; PANCREATIC NEOPLASMS; RECEPTOR, EPHA2; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84904398089     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2500     Document Type: Article

References (45)

1. Saif M, Lee Y and Kim R: Harnessing gemcitabine metabolism: a step towards personalized medicine for pancreatic cancer. Ther Adv Med Oncol 4: 341-346, 2012.
2. Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1: 27-31, 1995.
3. Bergers G and Benjamin LE: Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3: 401-410, 2003. (Pubitemid 37328844)
4. Maniotis AJ, Folberg R, Hess A, Seftor EA, Gardner LM, Pe'er J, Trent JM, Meltzer PS, et al: Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol 155: 739-752, 1999. (Pubitemid 29426820)
5. Wang W, Lin P, Han C, Cai W, Zhao X and Sun B: Vasculogenic mimicry contributes to lymph node metastasis of laryngeal squamous cell carcinoma. J Exp Clin Cancer Res 60: 2-9, 2010.
6. Millimaggi D, Marl M, D'Ascenzo S, Giusti I, Pavan A and Dolo V: Vasculogenic mimicry of human ovarian cancer cells: Role of CDl47. Int J Oncol 35: 1423-1428, 2009.
7. Clemente M, Pérez-Alenza MD, Illera JC, Illera JC and Peña L: Histological, immunohistological, and ultrastructural description of vasculogenic mimicry in canine mammary cancer. Vet Pathol 47: 265-274, 2010.
8. Cai XS, Jia YW, Jiong M and Tang RY: Tumor blood vessels formation in osteosarcoma: vasculogenesis mimicry. Chin J Med 117: 94-98, 2004.
9. Yue WY and Chen ZP: Does vasculogenic mimicry exist in astrocytoma? J Histochem Cytochem 539: 997-1002, 2005.
10. Sun W, Fan YZ, Zhang WZ and Ge CY: A pilot histomorphology and hemodynamic of vasculogenic mimicry in gallbladder carcinomas in vivo and in vitro. J Exp Clin Cancer Res 46: 2-11, 2011.
11. Yue WY and Chen ZP: Vasculogenic mimicry - potential target for tumor therapy. Ai Zheng 25: 914-916, 2006 (In Chinese).
12. Shirakawa K, Kobayashi H, Heike Y, Kawamoto S, Brechbiel MW, Kasumi F, Iwanaga T, et al: Hemodynamics in vasculogenic mimicry and angiogenesis of inflammatory breast cancer xenograft. Cancer Res 62: 560-566, 2002. (Pubitemid 34106432)
13. Hendrix MJ, Seftor EA, Meltzer PS, Gardner LM, Hess AR, Kirschmann DA, Schatteman GC, et al: Expression and functional signiicance of VE-cadherin in aggressive human melanoma cells: role in vasculogenic mimicry. Proc Natl Acad Sci USA 98: 8018-8023, 2001. (Pubitemid 32642679)
14. Hess AR, Seftor EA, Gruman LM, Kinch MS, Seftor RE and Hendrix MJ: VE-cadherin regulates EphA2 in aggressive melanoma cells through a novel signaling pathway: implications for vasculogenic mimicry. Cancer Biol Ther 5: 228-233, 2006. (Pubitemid 43327544)
15. Hess AR, Seftor EA, Gardner LM, Carles-Kinch K, Schneider GB, Seftor RE, Kinch MS, et al: Molecular regulation of tumor cell vasculogenic mimicry by tyrosine phosphorylation: role of epithelial cell kinase (Eck/EphA2). Cancer Res 61: 3250-3255, 2001. (Pubitemid 32695007)
16. Margaryan NV, Strizzi L, Abbott DE, Seftor EA, Rao MS, Hendrix MJ and Hess AR: EphA2 as a promoter of melanoma tumorigenicity. Cancer Biol Ther 8: 279-288, 2008.
17. Hess AR, Margaryan NV, Seftor EA and Hendrix MJ: Deciphering the signaling events that promote melanoma tumor cell vasculogenic mimicry and their link to embryonic vasculogenesis: role of the Eph receptors. Dev Dyn 236: 3283-3296, 2007. (Pubitemid 350276386)
18. Seftor RE, Seftor EA, Koshikawa N, Meltzer PS, Gardner LM, Bilban M, Stetler-Stevenson WG, et al: Cooperative interactions of laminin 5 gamma 2 chain, matrix metalloproteinase-2, and membrane type-1-matrix/metalloproteinase are required for mimicry of embryonic vasculogenesis by aggressive melanoma. Cancer Res 61: 6322-6327, 2001. (Pubitemid 32783230)
19. Seftor RE, Seftor EA, Kirschmann DA and Hendrix MJ: Targeting the tumor microenvironment with chemically modified tetracyclines: inhibition of laminin 5 gamma 2 chain promigratory fragments and vasculogenic mimicry. Mol Cancer Ther 1: 1173-1179, 2002.
20. Hess AR, Seftor EA, Seftor RE and Hendrix MJ: Phosphoinositide 3-kinase regulates membrane type 1-matrix metalloproteinase (MMP) and MMP-2 activity during melanoma cell vasculogenic mimicry. Cancer Res 63: 4757-4762, 2003. (Pubitemid 37022600)
21. Sood AK, Fletcher MS, Cofin JE, Yang M, Seftor EA, Gruman LM, Gershenson DM, et al: Functional role of matrix metalloproteinases in ovarian tumor cell plasticity. Am J Obstet Gynecol 190: 899-909, 2004. (Pubitemid 38561505)
22. Yue PY, Wong DY and Wu PK: The angiosuppressive effects of 20(R)-ginsenoside Rg3. Biochem Pharmacol 72: 437-445, 2006.
23. Han J, Hao F, Hao F, An Y, Xu Y, Xiaokaiti Y, Pan Y, et al: Ginsenoside Rg3 attenuates cell migration via inhibition of aquaporin 1 expression in PC-3M prostate cancer cells. Eur J Pharmacol 683: 27-34, 2012.
24. Kim JW, Jung SY, Kwon YH, Lee JH, Lee YM, Lee BY and Kwon SM: Ginsenoside Rg3 attenuates tumor angiogenesis via inhibiting bioactivities of endothelial progenitor cells. Cancer Biol Ther 13: 504-515, 2012.
25. Zhang C, Liu L, Yu Y, Chen B, Chen B, Tang C and Li X: Antitumor effects of ginsenoside Rg3 on human hepatocellular carcinoma cells. Mol Med Rep 5: 1295-1298, 2012.
26. Lee CK, Park KK, Chung AS and Chung WY: Ginsenoside Rg3 enhances the chemosensitivity of tumors to cisplatin by reducing the basal level of nuclear factor erythroid 2-related factor 2-mediated heme oxygenase-1/NAD(P)H quinone oxidoreductase-1 and prevents normal tissue damage by scavenging cisplatin-induced intracellular reactive oxygen species. Food Chem Toxicol 50: 2565-2574, 2012.
27. Liu JP, Lu D, Nicholson RC, Li PY and Wang F: Toxicity of a novel anti-tumor agent 20(S)-ginsenoside Rg3: a 26-week intramuscular repeated administration study in Beagle dogs. Food Chem Toxicol 49: 1718-1727, 2011.
28. Yuan HD, Quan HY, Zhang Y, Kim SH and Chung SH: 20(S)-Ginsenoside Rg3-induced apoptosis in HT-29 colon cancer cells is associated with AMPK signaling pathway. Mol Med Rep 3: 825-831, 2010.
29. Chen XP, Qian LL, Jiang H and Chen JH: Ginsenoside Rg3 inhibits CXCR4 expression and related migrations in a breast cancer cell line. Int J Clin Oncol 16: 519-523, 2011.
30. Greenberg E, Hershkovitz L, Itzhaki O, Hajdu S, Nemlich Y, Ortenberg R, Gefen N, et al: Regulation of cancer aggressive features in melanoma cells by microRNAs. PLoS One 6: e18936, 2011.
31. Folkman J: Tumor angiogenesis therapeutic implications. N Engl J Med 285: 1182-1186, 1971.
32. Van der Schaft DW, Seftor RE, Seftor EA, Hess AR, Gruman LM, Kirschmann DA, Yokoyama Y, et al: Effects of angiogenesis inhibitors on vascular network formation by human endothelial and melanoma cells. J Natl Cancer Inst 96: 1473-1477, 2004. (Pubitemid 39429672)
33. Chen LX, He YJ, Zhao SZ, Wu JG, Wang JT, Zhu LM, Lin TT, et al: Inhibition of tumor growth and vasculogenic mimicry by curcumin through downregulation of the EphA2/PI3K/MMP pathway in a murine choroidal melanoma model. Cancer Biol Ther 11: 229-235, 2011.
34. Wang HB. Lin YC, Zeng DE, Lin W, Hong CQ, Lin WZ and Chen JY: Inhibitory effect of ginsenoside Rg3 on the tube-like structure formation in human nasopharyngeal carcinoma HNE-1 cell line in vitro. Zhonghua Zhong Liu Za Zhi 32: 739-742, 2010 (In Chinese).
35. Sun B, Zhang S, Zhang D, Yin X, Wang S, Gu Y and Wang Y: Doxycycline influences microcirculatin patterns in B16 melanoma. Exp Biol Med (Maywood) 232: 1300-1307, 2007. (Pubitemid 350014419)
36. Guo HC, Bu HQ, Luo J, Wei WT, Liu DL, Chen H, Tong HF, et al: Emodin potentiates the antitumor effects of gemcitabine in PANC-1 pancreatic cancer xenograft model in vivo via inhibition of inhibitors of apoptosis. Int J Oncol 40: 1849-1857, 2012.
37. Ruf W, Seftor EA, Petrovan RJ, Weiss RM, Gruman LM, Margaryan NV, Seftor RE, et al: Differential role of tissuefactor pathway inhibitors 1 and 2 in melanoma vasculogenic mimicry. Cancer Res 63: 5381-5389, 2003. (Pubitemid 37139855)
38. Kirschmann DA, Seftor EA, Hardy KM, Seftor RE and Hendrix MJ: Molecular pathways: vasculogenic mimicry in tumor cells: diagnostic and therapeutic implications. Clin Cancer Res 18: 2726-2732, 2012.
39. Hendrix MJ, Seftor EA, Hess AR and Seftor RE: Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma. Nat Rev Cancer 3: 411-421, 2003. (Pubitemid 37328845)
40. Folberg R, Arbieva Z, Moses J, Hayee A, Sandal T, Kadkol S, Lin AY, et al: Tumor cell plasticity in uveal melanoma: microenvironment directed dampening of the invasive and metastatic genotype and phenotype accompanies the generation of vasculogenic mimicry patterns. Am J Pathol 169: 1376-1389, 2006. (Pubitemid 351194371)
41. Fan YZ and Sun W: Molecular regulation of vasculogenic mimicry in tumors and potential tumor-target therapy. World J Gastrointest Surg 2: 117-127, 2010.
42. Liu R, Cao Z, Tu J, Pan Y, Shang B, Zhang G, Bao M, et al: Lycorine hydrochloride inhibits metastatic melanoma cell-dominant vasculogenic mimicry. Pigment Cell Melanoma Res 25: 630-638, 2012.
43. Shin YM, Jung HJ, Choi WY and Lim CJ: Antioxidative, anti-inflammatory, and matrix metalloproteinase inhibitory activities of 20(S)-ginsenoside Rg3 in cultured mammalian cell lines. Mol Biol Rep 40: 269-279, 2013.
44. Xu TM, Cui MH, Xin Y, Gu LP, Jiang X, Su MM, Wang DD, et al: Inhibitory effect of ginsenoside Rg3 on ovarian cancer metastasis. Chin Med J 121: 1394-1397, 2008.
45. Chen MW, Ni L, Zhao XG and Niu XY: The inhibition of 20(R)-ginsenoside Rg3 on the expressions of angiogenesis factors proteins in human lung adenocarcinoma cell line A549 and HUVEC304 cell. Zhongguo Zhong Yao Za Zhi 30: 357-360, 2005 (In Chinese). (Pubitemid 44724709)